Apimeds Pharmaceuticals US, Inc. - Asset Resilience Ratio
Apimeds Pharmaceuticals US, Inc. (APUS) has an Asset Resilience Ratio of 1.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore APUS long-term investments to assets to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2025–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Asset Resilience Ratio has changed over time. See APUS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Apimeds Pharmaceuticals US, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see APUS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 1.06% |
| Total Liquid Assets | $1.50 Million | 1.06% |
Asset Resilience Insights
- Limited Liquidity: Apimeds Pharmaceuticals US, Inc. maintains only 1.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apimeds Pharmaceuticals US, Inc. Industry Peers by Asset Resilience Ratio
Compare Apimeds Pharmaceuticals US, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
SHE:000766 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
Annual Asset Resilience Ratio for Apimeds Pharmaceuticals US, Inc. (2025–2025)
The table below shows the annual Asset Resilience Ratio data for Apimeds Pharmaceuticals US, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.22% | $2.00 Million | $164.18 Million | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.